SCHEMBL4293582

SCHEMBL4293582

N#Cc1cccc(NC(=O)COc2ccc(Cl)cc2Cl)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.61
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
TP53 P04637 3/20 0.60
RAB9A P51151 3/20 0.60
LMNA P02545 1/20 0.60
MAPT P10636 5/20 0.59
ALDH1A1 P00352 2/20 0.59
HPGD P15428 3/20 0.56
HTT P42858 2/20 0.56
GAA P10253 1/20 0.56
THRB P10828 1/20 0.56
ALOX12 P18054 1/20 0.56
MRGPRX4 Q96LA9 1/20 0.56
NPC1 O15118 2/20 0.55
PKM P14618 2/20 0.55
MITF O75030 1/20 0.55
XBP1 P17861 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.54
TSHR P16473 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12218388 0.86 MAPT (0.72) MEN1KMT2ATP53RAB9ALMNA
SCHEMBL11084259 0.84 ALDH1A1 (0.57) KCNH2MEN1KMT2ARAB9ALMNA
SCHEMBL4296024 0.83 MEN1 (0.65) MEN1KMT2ATP53RAB9ALMNA
SCHEMBL18327156 0.82 MAPT (0.79) MEN1KMT2ATP53RAB9ALMNA
SCHEMBL4298332 0.81 RAB9A (0.63) MEN1KMT2ATP53RAB9ALMNA
SCHEMBL4295572 0.81 RAB9A (0.63) MEN1KMT2ATP53RAB9ALMNA
SCHEMBL2636219 0.80 KCNH2 (0.51) KCNH2MEN1KMT2ARAB9ALMNA
SCHEMBL4297524 0.80 MEN1 (0.61) MEN1KMT2ATP53RAB9ALMNA
SCHEMBL4298335 0.80 MEN1 (0.61) MEN1KMT2ATP53RAB9ALMNA
SCHEMBL27374650 0.80 MEN1 (0.84) MEN1KMT2ATP53RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090306078-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-12-10 US claimed
US-8394799-B2 Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2013-03-12 US disclosed
US-8394799-B2 Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2013-03-12 US disclosed
US-20090306078-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-12-10 US disclosed
US-20090306078-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-12-10 US disclosed
WO-2008004798-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306078-A1 COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT HIF1AN, HIF1A, VHL KCNH2 4675/4885MEN1 3620/4885KMT2A 1390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.